Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice
Open Access

Metronidazole-induced neurotoxicity

Danica Quickfall, Nick Daneman, Adam A. Dmytriw and David N. Juurlink
CMAJ October 25, 2021 193 (42) E1630; DOI: https://doi.org/10.1503/cmaj.201671
Danica Quickfall
Department of Medicine (Quickfall, Daneman, Juurlink), Sunnybrook Health Sciences Centre; Departments of Medicine and Paediatrics (Quickfall, Daneman, Juurlink), University of Toronto; Institute for Clinical Evaluative Sciences (ICES) (Daneman, Juurlink), Toronto, Ont.; Neuroendovascular Program (Dmytriw), Massachusetts General Hospital, Harvard Medical School, Boston, Mass.; Ontario Poison Centre (Juurlink), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick Daneman
Department of Medicine (Quickfall, Daneman, Juurlink), Sunnybrook Health Sciences Centre; Departments of Medicine and Paediatrics (Quickfall, Daneman, Juurlink), University of Toronto; Institute for Clinical Evaluative Sciences (ICES) (Daneman, Juurlink), Toronto, Ont.; Neuroendovascular Program (Dmytriw), Massachusetts General Hospital, Harvard Medical School, Boston, Mass.; Ontario Poison Centre (Juurlink), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam A. Dmytriw
Department of Medicine (Quickfall, Daneman, Juurlink), Sunnybrook Health Sciences Centre; Departments of Medicine and Paediatrics (Quickfall, Daneman, Juurlink), University of Toronto; Institute for Clinical Evaluative Sciences (ICES) (Daneman, Juurlink), Toronto, Ont.; Neuroendovascular Program (Dmytriw), Massachusetts General Hospital, Harvard Medical School, Boston, Mass.; Ontario Poison Centre (Juurlink), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David N. Juurlink
Department of Medicine (Quickfall, Daneman, Juurlink), Sunnybrook Health Sciences Centre; Departments of Medicine and Paediatrics (Quickfall, Daneman, Juurlink), University of Toronto; Institute for Clinical Evaluative Sciences (ICES) (Daneman, Juurlink), Toronto, Ont.; Neuroendovascular Program (Dmytriw), Massachusetts General Hospital, Harvard Medical School, Boston, Mass.; Ontario Poison Centre (Juurlink), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Metronidazole-induced neurotoxicity is underappreciated

Metronidazole, usually prescribed for anaerobic and protozoal infections, can uncommonly cause adverse effects involving the central nervous system. The exact mechanism is unclear. In 1 case–control study, the incidence of neurologic events was 0.25%, although this is likely an underestimate.1

Metronidazole-induced neurotoxicity can present with a variety of clinical syndromes

Common central nervous system features include ataxia, dysarthria and altered mental status, but rarer manifestations such as seizures, encephalopathy and cerebellar dysfunction have also been described.2 Peripheral neuropathy manifests as diminished sensation, numbness and neuropathic pain. Patients with central nervous system abnormalities have coexisting peripheral neuropathy in roughly one-third of cases.2

Dose and duration of treatment are the primary risk factors, but symptoms may appear early and with small doses

Case reports suggest the average duration of treatment before symptom onset is 6–7 weeks, but symptoms can appear within days of initiation.2,3 Patients receiving metronidazole for inflammatory bowel disease, osteomyelitis and large, undrained abscesses are at greatest risk of neurotoxicity due to long exposure. A review of 110 adult cases with metronidazole-induced encephalopathy found the median cumulative dose was 65.4 g, although there was wide variability (range 5–2000 g).2

Up to 90% of patients with central nervous system involvement have characteristic lesions on magnetic resonance imaging (MRI)

Typical radiologic findings are most commonly seen on T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI sequences. Symmetric, hyper-intense lesions of the dentate nuclei are commonly present, with lesions of the callosal splenium and dorsal pons of the same signal characteristics being the next most common abnormalities.2,4

Discontinuing metronidazole usually results in improvement

Most patients experience complete symptom resolution upon cessation of metronidazole, and complete or near-complete radiologic resolution occurs in about 75% of cases.2,4 The time course varies, but the symptoms of most patients resolve within 2 weeks.4

CMAJ invites submissions to “Five things to know about …” Submit manuscripts online at http://mc.manuscriptcentral.com/cmaj

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

    1. Daneman N,
    2. Cheng Y,
    3. Gomes T,
    4. et al
    . Metronidazole-associated neurologic events: a nested case-control study. Clin Infect Dis 2021;72:2095–100.
    1. Sørensen CG,
    2. Karlsson WK,
    3. Amin FM,
    4. et al
    . Metronidazole-induced encephalopathy: a systematic review. J Neurol 2020; 267:1–13.
    1. Kuriyama A,
    2. Jackson JL,
    3. Doi A,
    4. et al
    . Metronidazole-induced central nervous system toxicity: a systematic review. Clin Neuropharmacol 2011;34:241–7.
    1. Patel L,
    2. Batchala P,
    3. Almardawi R,
    4. et al
    . Acute metronidazole-induced neurotoxicity: an update on MRI findings. Clin Radiol 2020;75:202–8.

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire